We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Novel Approach to Bladder Cancer Chemotherapy Based on Arginine Depletion

By LabMedica International staff writers
Posted on 21 Dec 2016
Studies conducted on arginine-dependent bladder cancer cell cultures and mouse xenografts revealed that this cancer is highly susceptible to treatment with a drug compound comprising the enzyme arginine deiminase (ADI) conjugated to polyethylene glycol (PEG).

Loss of argininosuccinate synthetase 1 (ASS1), a key enzyme for arginine synthesis, which occurs more than 90% of all bladder cancers, makes the cancer cells dependent on extracellular arginine. More...
One approach towards treating ASS1-deficient cancer is to remove its source of external arginine. One way of doing this in vivo is by treating the animal with the arginine-degrading enzyme pegylated arginine deiminase (ADI-PEG 20).

ADI-PEG 20 was designed by Polaris Pharmaceuticals, Inc. (San Diego, CA, USA) to deplete the external supply of arginine, causing arginine-dependent cancer cells to die while leaving the patient’s normal cells unharmed. It is a novel protein therapeutic that has demonstrated anti-tumor activity and safety in clinical trials of patients with various cancers. ADI was conjugated with polyethylene glycol (PEG) of 20,000 dalton molecular weight to increase the circulating half-life and decrease antigenicity of ADI. Similar PEGylation technology has been used with microbially derived therapeutic proteins for systemic delivery of other anticancer drugs. Conjugating ADI with PEG also allowed for the drug to be administered by intramuscular injection, which avoided possible complications known to be associated with multiple intravenous administrations.

Investigators at the University of California, San Diego (USA) evaluated ASS1 expression and effects of ASS1 loss in bladder cancer, which despite affecting more than 70,000 people in the United States annually, has limited therapeutic options.

The authors reported in the December 12, 2016, online edition of The American Journal of Pathology that they detected ASS1 loss in conventional and micropapillary urothelial carcinoma, small cell, and squamous cell carcinoma subtypes of invasive bladder cancer, as well as in T24, J82, and UM-UC-3 but not in 5637, RT112, and RT4 cell lines. ASS1-deficient cells showed preferential sensitivity to ADI-PEG 20, evidenced by decreased colony formation, reduced cell viability, and increased sub-G1 fractions.

ADI-PEG 20 treatment of mice bearing contralateral flank UM-UC-3 (ASS1 deficient) and RT112 (normal ASS1) xenografts selectively arrested tumor growth in the UM-UC-3 xenografts.

"There is a major unmet need to identify additional therapies for bladder cancer patients that includes agents that can target both conventional urothelial carcinoma and less common subtypes of bladder cancer. Our findings suggest that arginine dependency in bladder cancer may be a useful mechanism to selectively target a subset of these cancers using ADI-PEG 20, although further investigation into the mediators of this effect and the role of combination therapy, including chemotherapy, to enhance efficacy is required," said senior author Dr. Donna Hansel, professor of pathology at the University of California, San Diego. "Our results suggest that arginine deprivation may be a useful strategy for treating bladder cancer and show that ADI-PEG 20 functions through a novel signaling mechanism that includes the pathway mediated by the general control nonderepressible II kinase that controls autophagy and apoptosis."

Related Links:
Polaris Pharmaceuticals
University of California, San Diego

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
ESR Analyzer
miniiSED™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.